Literature DB >> 26763789

New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.

Pertti Heikman1, Mira Sundström2, Anna Pelander2, Ilkka Ojanperä2.   

Abstract

OBJECTIVE: At present, polydrug abuse comprises, besides traditional illicit drugs, new psychoactive substances (NPS) and non-prescribed psychotropic medicines (N-PPM). Polydrug abuse was comprehensively evaluated among opioid-dependent patients undergoing opioid maintenance treatment (OMT).
METHODS: Two hundred consecutively collected urine samples from 82 OMT patients (52 male) treated with methadone or buprenorphine-naloxone medication were studied using a liquid chromatography/time-of-flight mass spectrometry screening method. The method enables simultaneous detection of hundreds of abused substances covering the traditional drugs of abuse and many NPS as well as N-PPM.
RESULTS: Ninety-two (45.8%) samples were positive for the abused substances. Benzodiazepines (29.0%), amphetamines (19.5%), cannabinoids (17.0%), NPS (13.0%), N-PPM (9.0%), and opioids (9.0%) were detected in different combinations. The simultaneous occurrence of up to three groups of abused substances was common (40.0%), and in one sample, all six groups were found. The stimulant NPS alpha-pyrrolidinovalerophenone was found in 10.0% and the sedative N-PPM pregabalin in 4.0% of the samples. The patients were seldom aware of what particular NPS they had abused.
CONCLUSIONS: A widespread occurrence of abused substances beyond the ordinary was revealed. Identifying these patients is essential as polydrug abuse is a safety risk to the patient and may cause attrition from OMT.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  high-resolution mass spectrometry; new psychoactive substances; opioid maintenance treatment; polydrug abuse; α-PVP

Mesh:

Substances:

Year:  2016        PMID: 26763789     DOI: 10.1002/hup.2512

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  10 in total

1.  Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.

Authors:  Zoe M Weinstein; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong Kim; Gabriela Gryczynski; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2016-11-05       Impact factor: 4.492

2.  New Psychoactive Substances Consumption in Opioid-Use Disorder Patients.

Authors:  Maria Alías-Ferri; Manuela Pellegrini; Emilia Marchei; Roberta Pacifici; Maria Concetta Rotolo; Simona Pichini; Clara Pérez-Mañá; Esther Papaseit; Robert Muga; Francina Fonseca; Marta Torrens; Magí Farré
Journal:  Biology (Basel)       Date:  2022-04-22

3.  Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast.

Authors:  Pablo K Valente; Angela R Bazzi; Ellen Childs; Peter Salhaney; Joel Earlywine; Jennifer Olson; Dea L Biancarelli; Brandon D L Marshall; Katie B Biello
Journal:  Int J Drug Policy       Date:  2020-09-07

4.  Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine.

Authors:  Pertti Kalevi Heikman; Leea Hellevi Muhonen; Ilkka Antero Ojanperä
Journal:  BMC Psychiatry       Date:  2017-07-06       Impact factor: 3.630

5.  Synthetic cannabinoids use in a sample of opioid-use disorder patients.

Authors:  María Alías-Ferri; Manuela Pellegrini; Emilia Marchei; Roberta Pacifici; Maria Concetta Rotolo; Simona Pichini; Clara Pérez-Mañá; Esther Papaseit; Robert Muga; Francina Fonseca; Magi Farré; Marta Torrens
Journal:  Front Psychiatry       Date:  2022-08-03       Impact factor: 5.435

6.  Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment.

Authors:  Michael Specka; Thomas Kuhlmann; Jürgen Sawazki; Udo Bonnet; Renate Steinert; Monika Cybulska-Rycicki; Helmut Eich; Benita Zeiske; Antje Niedersteberg; Luzia Schaaf; Norbert Scherbaum
Journal:  Front Psychiatry       Date:  2020-07-07       Impact factor: 4.157

7.  Pregabalin Abuse in Combination With Other Drugs: Monitoring Among Methadone Patients.

Authors:  Massimo Lancia; Angela Gambelunghe; Alessio Gili; Mauro Bacci; Kyriaki Aroni; Cristiana Gambelunghe
Journal:  Front Psychiatry       Date:  2020-02-11       Impact factor: 4.157

8.  Opioid and Polydrug Use Among Patients in Opioid Maintenance Treatment.

Authors:  Siv-Elin Leirvaag Carlsen; Linn-Heidi Lunde; Torbjørn Torsheim
Journal:  Subst Abuse Rehabil       Date:  2020-01-29

Review 9.  Flakka: New Dangerous Synthetic Cathinone on the Drug Scene.

Authors:  Jiri Patocka; Bingshu Zhao; Wenda Wu; Blanka Klimova; Martin Valis; Eugenie Nepovimova; Kamil Kuca
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

10.  Knowledge and Use of Novel Psychoactive Substances in an Italian Sample with Substance Use Disorders.

Authors:  Deborah Dal Farra; Alice Valdesalici; Giancarlo Zecchinato; Alfio De Sandre; Diego Saccon; Pierluigi Simonato; Ornella Corazza; Giovanni Martinotti; Andrew L Smith; Marco Solmi
Journal:  Int J Environ Res Public Health       Date:  2022-01-14       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.